Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 71, No 6 (2020)
Original paper
Submitted: 2020-11-02
Accepted: 2020-11-16
Published online: 2020-12-02
View PDF Download PDF file
Get Citation

Assessing the blood concentration of new adipocytokines in patients with ischaemic stroke

Aleksandra Kazimierczak-Kabzińska1, Bogdan Marek2, Halina Borgiel-Marek3, Dariusz Kajdaniuk2, Beata Kos-Kudła2
DOI: 10.5603/EP.a2020.0082
·
Pubmed: 33283259
·
Endokrynol Pol 2020;71(6):504-511.
Affiliations
  1. Department of Neurology with Stroke Ward, Provincial Specialist Hospital, Bełchatów, Poland
  2. Department of Pathophysiology and Endocrinology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Zabrze, Poland
  3. Department of Craniomaxillofacial and Oral Surgery, Medical University of Silesia in Katowice, Katowice, Poland

open access

Vol 71, No 6 (2020)
Original Paper
Submitted: 2020-11-02
Accepted: 2020-11-16
Published online: 2020-12-02

Abstract

Introduction: Ischaemic stroke (IS) is a disease that is a common cause of death and one of the most common causes of disability in adults. There is a continuous need to conduct stroke pathogenesis studies. A certain role here can be attributed to adipose-derived hormones. The aim of this paper is to assess the blood concentration for selected adipocytokines: omentin-1, irisin, protein-1 related with C1q/TNF (CTRP1), vaspin and nesfatin-1 in IS patients, and an attempt to define their role as risk factors for ischaemic stroke.

Material and methods: The study included 46 patients with ischaemic stroke (27 females, 19 males, average 67.6 years of age). The control group consisted of 32 patients (16 females, 16 males, average 64.1 years of age) who had never had cerebrovascular diseases.

Results: The concentration of omentin-1 and CTRP1 in the group of stroke patients was higher than in the control group, whereas the concentrations of nesfatin-1 and irisin was significantly lower than in the control group. The vaspin level was similar in both groups of patients. Statistical analysis using logistic regression allows us to find that CTRP1 can be a significant stroke risk factor. A statistically significant positive correlation was found between the concentration of CTRP1 and NIHSS. However, no correlation between the concentration of other adipocytokines under investigation and the severity of ischaemic stroke was found.

Conclusions: From among the adipocytokines under investigation, higher concentrations of omentin-1 and CTRP1 and lower blood concentrations of nesfatin-1, irisin significantly increase the odds of getting to the group of ischaemic patients. It seems that CTRP1 can be an independent predictive factor of IS.

Abstract

Introduction: Ischaemic stroke (IS) is a disease that is a common cause of death and one of the most common causes of disability in adults. There is a continuous need to conduct stroke pathogenesis studies. A certain role here can be attributed to adipose-derived hormones. The aim of this paper is to assess the blood concentration for selected adipocytokines: omentin-1, irisin, protein-1 related with C1q/TNF (CTRP1), vaspin and nesfatin-1 in IS patients, and an attempt to define their role as risk factors for ischaemic stroke.

Material and methods: The study included 46 patients with ischaemic stroke (27 females, 19 males, average 67.6 years of age). The control group consisted of 32 patients (16 females, 16 males, average 64.1 years of age) who had never had cerebrovascular diseases.

Results: The concentration of omentin-1 and CTRP1 in the group of stroke patients was higher than in the control group, whereas the concentrations of nesfatin-1 and irisin was significantly lower than in the control group. The vaspin level was similar in both groups of patients. Statistical analysis using logistic regression allows us to find that CTRP1 can be a significant stroke risk factor. A statistically significant positive correlation was found between the concentration of CTRP1 and NIHSS. However, no correlation between the concentration of other adipocytokines under investigation and the severity of ischaemic stroke was found.

Conclusions: From among the adipocytokines under investigation, higher concentrations of omentin-1 and CTRP1 and lower blood concentrations of nesfatin-1, irisin significantly increase the odds of getting to the group of ischaemic patients. It seems that CTRP1 can be an independent predictive factor of IS.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

ischaemic stroke; adipocytokines; omentin-1; nesfatin-1; CTRP1; irisin; vaspin

About this article
Title

Assessing the blood concentration of new adipocytokines in patients with ischaemic stroke

Journal

Endokrynologia Polska

Issue

Vol 71, No 6 (2020)

Article type

Original paper

Pages

504-511

Published online

2020-12-02

Page views

1117

Article views/downloads

894

DOI

10.5603/EP.a2020.0082

Pubmed

33283259

Bibliographic record

Endokrynol Pol 2020;71(6):504-511.

Keywords

ischaemic stroke
adipocytokines
omentin-1
nesfatin-1
CTRP1
irisin
vaspin

Authors

Aleksandra Kazimierczak-Kabzińska
Bogdan Marek
Halina Borgiel-Marek
Dariusz Kajdaniuk
Beata Kos-Kudła

References (50)
  1. Łabuz-Roszak B, Starostka-Tatar A, Lasek-Bal A, et al. Diagnostics, treatment and secondary prevention of ischemic stroke in the Silesian Province, Poland between 2009 and 2015. Neurol Neurochir Pol. 2018; 52(2): 235–242.
    CrossRefPubMed
  2. Chwalba A, Machura E, Ziora K, et al. The role of adipokines in the pathogenesis and course of selected respiratory diseases. Endokrynol Pol. 2019; 70(6): 504–510.
    CrossRefPubMed
  3. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89(6): 2548–2556.
    CrossRefPubMed
  4. Baranowska-Bik A, Kalisz M, Martyńska L, et al. Plasma adiponectin array in women with Alzheimer's disease. Endokrynol Pol. 2018; 69(5): 550–559.
    CrossRefPubMed
  5. Prugger C, Luc G, Haas B, et al. PRIME Study Group. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol. 2012; 71(4): 478–486.
    CrossRefPubMed
  6. Głogowska-Szeląg J, Kos-Kudła B, Marek B, et al. Assessment of selected adipocytokines in obese women with postmenopausal osteoporosis. Endokrynol Pol. 2019; 70(6): 478–483.
    CrossRefPubMed
  7. Olszanecka-Glinianowicz M, Kocełak P, Orlik B, et al. Nowe adipokiny — korzystne czy niekorzystne w aspekcie patogenezy insulinooporności? Endokr Otył Zab Przem Mat. 2009; 5(4): 236–242.
  8. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007; 56(6): 1655–1661.
    CrossRefPubMed
  9. Pukajło K, Kolackov K, Łaczmański Ł, et al. [Irisin — a new mediator of energy homeostasis]. Postepy Hig Med Dosw (Online). 2015; 69: 233–242.
    CrossRefPubMed
  10. Jeong E, Youn BS, Kim DW, et al. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J Clin Endocrinol Metab. 2010; 95(4): 1869–1875.
    CrossRefPubMed
  11. Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine. 2012; 41(2): 176–182.
    CrossRefPubMed
  12. Shimizu H, Oh-I S, Hashimoto K, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology. 2009; 150(2): 662–671.
    CrossRefPubMed
  13. Szlachcic A, Surmiak M, Majka J, et al. Nesfatin-1: a new hormone in the control of food intake and the mechanism of damage and protection of gastric mucosa. Gastroenterol Rev. 2012; 6: 339–350.
    CrossRef
  14. Schäffler A, Buechler C. CTRP family: linking immunity to metabolism. Trends Endocrinol Metab. 2012; 23(4): 194–204.
    CrossRefPubMed
  15. Kazimierczak-Kabzińska A, Kajdaniuk D, Siemińska L, et al. Selected adipose tissue hormones in the blood of patients with ischaemic cerebral stroke. Endokrynol Pol. 2020; 71(1): 21–26.
    CrossRefPubMed
  16. Bienek R, Marek B, Kajdaniuk D, et al. Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynol Pol. 2012; 63(5): 338–345.
    PubMed
  17. Shang FJ, Wang JP, Liu XT, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011; 16(8): 657–662.
    CrossRefPubMed
  18. Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012; 4(1): 37.
    CrossRefPubMed
  19. Yoo HJ, Hwang SY, Hong HoC, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011; 10: 103.
    CrossRefPubMed
  20. Zhong X, Zhang Hy, Tan H, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011; 32(7): 873–878.
    CrossRefPubMed
  21. Wu DM, Wang S, Wen X, et al. Impact of serum omentin-1 levels on functional prognosis in nondiabetic patients with ischemic stroke. Am J Transl Res. 2019; 11(3): 1854–1863.
    PubMed
  22. Xu T, Zuo P, Cao L, et al. Omentin-1 is Associated with Carotid Plaque Instability among Ischemic Stroke Patients. J Atheroscler Thromb. 2018; 25(6): 505–511.
    CrossRefPubMed
  23. Huh JY, Siopi A, Mougios V, et al. Irisin in response to exercise in humans with and without metabolic syndrome. J Clin Endocrinol Metab. 2015; 100(3): E453–E457.
    CrossRefPubMed
  24. Moraes C, Leal VO, Marinho SM, et al. Resistance exercise training does not affect plasma irisin levels of hemodialysis patients. Horm Metab Res. 2013; 45(12): 900–904.
    CrossRefPubMed
  25. Norheim F, Langleite TM, Hjorth M, et al. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 2014; 281(3): 739–749.
    CrossRefPubMed
  26. Chen Jq, Huang Yy, Gusdon AM, et al. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015; 14: 2.
    CrossRefPubMed
  27. Anastasilakis AD, Koulaxis D, Kefala N, et al. Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism. 2017; 73: 1–8.
    CrossRefPubMed
  28. Zhang M, Chen P, Chen S, et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci. 2014; 18(11): 1567–1572.
    PubMed
  29. Emanuele E, Minoretti P, Pareja-Galeano H, et al. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. Am J Med. 2014; 127(9): 888–890.
    CrossRefPubMed
  30. Li DJ, Li YH, Yuan HB, et al. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism. 2017; 68: 31–42.
    CrossRefPubMed
  31. Jin Z, Guo P, Li X, et al. Neuroprotective effects of irisin against cerebral ischemia/ reperfusion injury via Notch signaling pathway. Biomed Pharmacother. 2019; 120: 109452.
    CrossRefPubMed
  32. Tu WJ, Qiu HC, Cao JL, et al. Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke. Neurotherapeutics. 2018; 15(4): 1158–1167.
    CrossRefPubMed
  33. Li Q, Chen R, Moriya J, et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res. 2008; 36(4): 625–629.
    CrossRefPubMed
  34. Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008; 57(2): 372–377.
    CrossRefPubMed
  35. Klöting N, Kovacs P, Kern M, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011; 54(7): 1819–1823.
    CrossRefPubMed
  36. Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol. 2009; 160(1): 65–70.
    CrossRefPubMed
  37. Li HL, Peng WH, Cui ST, et al. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin Chem Lab Med. 2011; 49(9): 1547–1554.
    CrossRefPubMed
  38. Aust G, Richter O, Rohm S, et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis. 2009; 204(1): 262–266.
    CrossRefPubMed
  39. Kadoglou NPE, Fotiadis G, Lambadiari V, et al. Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis. Peptides. 2014; 57: 12–16.
    CrossRefPubMed
  40. Cura HS, Özdemir HH, Demir CF, et al. Investigation of vaspin level in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014; 23(3): 453–456.
    CrossRefPubMed
  41. Yosten GLC, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009; 297(2): R330–R336.
    CrossRefPubMed
  42. Dai H, Li X, He T, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides. 2008; 46: 167–171.
    CrossRefPubMed
  43. Kuyumcu MS, Kuyumcu A, Yayla Ç, et al. Nesfatin-1 levels in patients with slow coronary flow. Kardiol Pol. 2018; 76(2): 401–405.
    CrossRefPubMed
  44. Ding S, Qu W, Dang S, et al. Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease. Med Sci Monit. 2015; 21: 987–991.
    CrossRefPubMed
  45. Kuyumcu A. The relationship between nesfatin-1 and carotid artery stenosis. Scand Cardiovasc J. 2018; 52(6): 328–334.
    CrossRefPubMed
  46. Erfani S, Moghimi A, Aboutaleb N, et al. Protective effects of Nesfatin-1 peptide on cerebral ischemia reperfusion injury via inhibition of neuronal cell death and enhancement of antioxidant defenses. Metab Brain Dis. 2019; 34(1): 79–85.
    CrossRefPubMed
  47. Jeon JHo, Kim Ky, Kim JH, et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008; 22(5): 1502–1511.
    CrossRefPubMed
  48. Tang JN, Shen DL, Liu CL, et al. Plasma levels of C1q/TNF-related protein 1 and interleukin 6 in patients with acute coronary syndrome or stable angina pectoris. Am J Med Sci. 2015; 349(2): 130–136.
    CrossRefPubMed
  49. Lu L, Zhang RY, Wang XQ, et al. C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. Eur Heart J. 2016; 37(22): 1762–1771.
    CrossRefPubMed
  50. Muendlein A, Leiherer A, Saely C, et al. The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events. Atherosclerosis. 2019; 286: 1–6.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl